Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Breast 2

Conditions

Prostatic Neoplasms 1Myofibroma 1Castration-resistant Prostate Cancer, Advanced Breast Cancer 1Breast Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × LFA102 monoclonal antibody × Clear all
NCT01338831 2020-12-17

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Novartis

Phase 1 Completed
73 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms, Myofibroma

NCT01610050 2014-11-11

A Phase I Study of LFA102 in Japanese Patients

Novartis

Phase 1 Completed
14 enrolled
BreastGenitourinary

Castration-resistant Prostate Cancer, Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡